STOCK TITAN

Meihua International Medical Technologies Co., Ltd. Financials

MHUA
Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Meihua International Medical Technologies Co., Ltd. (MHUA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MHUA FY2024

A receivables-heavy working-capital model and minimal leverage make reported liquidity look stronger than immediate cash flexibility.

In FY2024 cash conversion, reported profit finally turned into cash: operating cash flow reached $14.6M while free cash flow was $14.5M. But working-capital quality is still the real hinge, because receivables remained $78.7M against revenue of $96.9M, so the strong current ratio reflects customer credit as much as ready cash.

FY2022's profit drop was driven more by overhead than by demand: revenue stayed near $103.3M, yet SG&A jumped to $12.5M. That pushed operating margin down to 10.5% from 25.2%, which says earnings were highly sensitive to cost discipline once gross margin weakened.

Solvency is conservative: liabilities were only $27.3M against equity of $159.0M. Yet the balance sheet is receivables-heavy, not inventory-heavy; inventory was just $1.4M and cash was $17.3M, so short-term strength depends more on collections than on stock turnover.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 52 / 100
Financial Profile 52/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Meihua International Medical Technologies Co., Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
54

Meihua International Medical Technologies Co., Ltd. has an operating margin of 13.4%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is down from 14.8% the prior year.

Growth
0

Meihua International Medical Technologies Co., Ltd.'s revenue declined 36.2% year-over-year, from $96.9M to $61.8M. This contraction results in a growth score of 0/100.

Leverage
100

Meihua International Medical Technologies Co., Ltd. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
100

With a current ratio of 8.41, Meihua International Medical Technologies Co., Ltd. holds $8.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow
38

Meihua International Medical Technologies Co., Ltd. has a free cash flow margin of 0.9%, earning a moderate score of 38/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
23

Meihua International Medical Technologies Co., Ltd. generates a 3.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 23/100. This is down from 6.8% the prior year.

Altman Z-Score Safe
15.96

Meihua International Medical Technologies Co., Ltd. scores 15.96, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($425.4M) relative to total liabilities ($18.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral
4/9

Meihua International Medical Technologies Co., Ltd. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality
0.08x

For every $1 of reported earnings, Meihua International Medical Technologies Co., Ltd. generates $0.08 in operating cash flow ($570K OCF vs $6.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe
34.3x

Meihua International Medical Technologies Co., Ltd. earns $34.3 in operating income for every $1 of interest expense ($8.3M vs $242K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$61.8M
YoY-36.2%
5Y CAGR-7.1%

Meihua International Medical Technologies Co., Ltd. generated $61.8M in revenue in fiscal year 2025. This represents a decrease of 36.2% from the prior year.

EBITDA
$8.8M
YoY-40.6%
5Y CAGR-18.1%

Meihua International Medical Technologies Co., Ltd.'s EBITDA was $8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 40.6% from the prior year.

Net Income
$6.8M
YoY-37.5%
5Y CAGR-18.7%

Meihua International Medical Technologies Co., Ltd. reported $6.8M in net income in fiscal year 2025. This represents a decrease of 37.5% from the prior year.

EPS (Diluted)
$18.04

Meihua International Medical Technologies Co., Ltd. earned $18.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 54.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$554K
YoY-96.2%
5Y CAGR-18.2%

Meihua International Medical Technologies Co., Ltd. generated $554K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 96.2% from the prior year.

Cash & Debt
$15.2M
YoY-12.3%
5Y CAGR+16.1%

Meihua International Medical Technologies Co., Ltd. held $15.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
697,914

Meihua International Medical Technologies Co., Ltd. had 697,914 shares outstanding in fiscal year 2025. This represents a decrease of 97.8% from the prior year.

Margins & Returns

Gross Margin
31.0%
YoY-3.4pp
5Y CAGR-10.7pp

Meihua International Medical Technologies Co., Ltd.'s gross margin was 31.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.4 percentage points from the prior year.

Operating Margin
13.4%
YoY-1.4pp
5Y CAGR-12.9pp

Meihua International Medical Technologies Co., Ltd.'s operating margin was 13.4% in fiscal year 2025, reflecting core business profitability. This is down 1.4 percentage points from the prior year.

Net Margin
11.0%
YoY-0.2pp
5Y CAGR-10.4pp

Meihua International Medical Technologies Co., Ltd.'s net profit margin was 11.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.2 percentage points from the prior year.

Return on Equity
3.6%
YoY-3.2pp
5Y CAGR-18.9pp

Meihua International Medical Technologies Co., Ltd.'s ROE was 3.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.2 percentage points from the prior year.

Capital Allocation

R&D Spending
$2.4M
YoY-31.0%
5Y CAGR-0.9%

Meihua International Medical Technologies Co., Ltd. invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 31.0% from the prior year.

Share Buybacks
N/A
Capital Expenditures
$16K
YoY-88.3%
5Y CAGR-66.7%

Meihua International Medical Technologies Co., Ltd. invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 88.3% from the prior year.

MHUA Income Statement

Metric Q4'25 Q2'25 Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q4'21
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A N/A N/A N/A N/A
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income N/A N/A N/A N/A N/A N/A N/A N/A
EPS (Diluted) N/A N/A N/A N/A N/A N/A N/A N/A

MHUA Balance Sheet

Metric Q4'25 Q2'25 Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q4'21
Total Assets $207.2M+8.7% $190.6M+2.3% $186.2M+3.9% $179.2M+4.2% $171.9M+5.7% $162.6M-0.6% $163.6M+19.5% $136.9M
Current Assets $153.6M+4.9% $146.3M+2.0% $143.4M+1.5% $141.3M+6.9% $132.2M0.0% $132.3M-2.3% $135.3M+39.1% $97.3M
Cash & Equivalents $15.2M-10.3% $16.9M-2.2% $17.3M-6.5% $18.5M+9.2% $16.9M-5.2% $17.9M-33.2% $26.7M+228.1% $8.1M
Inventory $1.7M+54.9% $1.1M-21.9% $1.4M+29.1% $1.1M-32.5% $1.6M-1.8% $1.6M+46.8% $1.1M-10.3% $1.3M
Accounts Receivable $84.3M-2.6% $86.6M+10.1% $78.7M-4.7% $82.6M+5.1% $78.6M-0.6% $79.1M+14.7% $68.9M+2.7% $67.1M
Goodwill N/A N/A $7.9M N/A N/A N/A N/A N/A
Total Liabilities $18.3M-28.8% $25.6M-6.0% $27.3M-7.9% $29.6M+18.0% $25.1M+8.0% $23.2M-6.7% $24.9M-14.4% $29.1M
Current Liabilities $18.3M-28.8% $25.6M-6.0% $27.3M-7.9% $29.6M+18.0% $25.1M+8.0% $23.2M-3.9% $24.2M-16.9% $29.1M
Long-Term Debt N/A N/A N/A N/A N/A N/A $725K N/A
Total Equity $188.9M+14.5% $164.9M+3.8% $159.0M+6.3% $149.6M+2.2% $146.3M+5.4% $138.9M+0.6% $138.1M+28.2% $107.8M
Retained Earnings $111.9M+3.3% $108.3M+2.9% $105.2M+6.0% $99.3M+4.9% $94.6M+4.7% $90.4M+8.5% $83.3M+7.4% $77.6M

MHUA Cash Flow Statement

Metric Q4'25 Q2'25 Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q4'21
Operating Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

MHUA Financial Ratios

Metric Q4'25 Q2'25 Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q4'21
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A N/A N/A N/A
Current Ratio 8.41+2.7 5.71+0.4 5.26+0.5 4.78-0.5 5.27-0.4 5.70+0.1 5.60+2.3 3.34
Debt-to-Equity 0.10-0.1 0.16-0.0 0.17-0.0 0.20+0.0 0.170.0 0.17+0.2 0.01-0.3 0.27
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Similar Companies

Frequently Asked Questions

Meihua International Medical Technologies Co., Ltd. (MHUA) reported $61.8M in total revenue for fiscal year 2025. This represents a -36.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Meihua International Medical Technologies Co., Ltd. (MHUA) revenue declined by 36.2% year-over-year, from $96.9M to $61.8M in fiscal year 2025.

Yes, Meihua International Medical Technologies Co., Ltd. (MHUA) reported a net income of $6.8M in fiscal year 2025, with a net profit margin of 11.0%.

Meihua International Medical Technologies Co., Ltd. (MHUA) reported diluted earnings per share of $18.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Meihua International Medical Technologies Co., Ltd. (MHUA) had EBITDA of $8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Meihua International Medical Technologies Co., Ltd. (MHUA) had a gross margin of 31.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Meihua International Medical Technologies Co., Ltd. (MHUA) had an operating margin of 13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Meihua International Medical Technologies Co., Ltd. (MHUA) had a net profit margin of 11.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Meihua International Medical Technologies Co., Ltd. (MHUA) has a return on equity of 3.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Meihua International Medical Technologies Co., Ltd. (MHUA) generated $554K in free cash flow during fiscal year 2025. This represents a -96.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Meihua International Medical Technologies Co., Ltd. (MHUA) generated $570K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Meihua International Medical Technologies Co., Ltd. (MHUA) had $207.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Meihua International Medical Technologies Co., Ltd. (MHUA) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Meihua International Medical Technologies Co., Ltd. (MHUA) invested $2.4M in research and development during fiscal year 2025.

Meihua International Medical Technologies Co., Ltd. (MHUA) had 697,914 shares outstanding as of fiscal year 2025.

Meihua International Medical Technologies Co., Ltd. (MHUA) had a current ratio of 8.41 as of fiscal year 2025, which is generally considered healthy.

Meihua International Medical Technologies Co., Ltd. (MHUA) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Meihua International Medical Technologies Co., Ltd. (MHUA) had a return on assets of 3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Meihua International Medical Technologies Co., Ltd. (MHUA) has an Altman Z-Score of 15.96, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Meihua International Medical Technologies Co., Ltd. (MHUA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Meihua International Medical Technologies Co., Ltd. (MHUA) has an earnings quality ratio of 0.08x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Meihua International Medical Technologies Co., Ltd. (MHUA) has an interest coverage ratio of 34.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Meihua International Medical Technologies Co., Ltd. (MHUA) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top